open access

Vol 5, No 2 (2001)
Prace oryginalne
Published online: 2001-06-15
Get Citation

The Impact of Trandolapryl on Some Metabolic Disturbances and Endothelium Dysfunction in Non-treated Essential Hypertensive Patients

Marek Kretowicz, Małgorzata Ukleja-Adamowicz, Paweł Stróżecki, Krzysztof Buczkowski, Katarzyna Klucz, Ryszard Paczuski, Grażyna Odrowąż-Sypniewska, Jacek Manitius
Nadciśnienie tętnicze 2001;5(2):115-124.

open access

Vol 5, No 2 (2001)
Prace oryginalne
Published online: 2001-06-15

Abstract

Background Essential hypertension usually coexists with insulin resistance, which is a key factor for increased sympathetic nervous system activity, visceral obesity, composed metabolic disturbances and endothelial dysfunction. The aim of the study was to evaluate the impact of trandolapril on metabolic disorders and endothelial injury.

Material and methods We examined 13 ambulatory patients with non-treated essential hypertension. The control group was of 14 healthy volunteers matched with age and sex. The anthropometric parameters were obtained. The 24 hour urine collection was assayed for albuminuria, creatinine and NAG excretion. The next day fasting blood was withdrawn for biochemistry, insulin, thrombomodulin, tissue plasminogen activator and vWF:Ag. The examination was repeated after 3 months of trandolapril oral 2 mg per day therapy.

Results The hypertensive group was characterized with a number of abnormalities, which stand for polymetabolic syndrome. After 3 months therapy the significant decrease of HbA1c (%) (6,01 ± 0,45 vs. 5,66 ± 0,41; p < 0,05) and increase of vWF:Ag (%) (148,08 ± 65,10 vs. 306,77 ± ± 146,63; p < 0,01) were observed.

Conclusions Our study suggests the advantage of trandolapril monotherapy on carbohydrate metabolism seen in polymetabolic syndrome but not on endothelial function despite satisfactory blood pressure control. We observed significant increase of vWF:Ag level which may be a local effect of ACE inhibitor on already injured endothelium.

Abstract

Background Essential hypertension usually coexists with insulin resistance, which is a key factor for increased sympathetic nervous system activity, visceral obesity, composed metabolic disturbances and endothelial dysfunction. The aim of the study was to evaluate the impact of trandolapril on metabolic disorders and endothelial injury.

Material and methods We examined 13 ambulatory patients with non-treated essential hypertension. The control group was of 14 healthy volunteers matched with age and sex. The anthropometric parameters were obtained. The 24 hour urine collection was assayed for albuminuria, creatinine and NAG excretion. The next day fasting blood was withdrawn for biochemistry, insulin, thrombomodulin, tissue plasminogen activator and vWF:Ag. The examination was repeated after 3 months of trandolapril oral 2 mg per day therapy.

Results The hypertensive group was characterized with a number of abnormalities, which stand for polymetabolic syndrome. After 3 months therapy the significant decrease of HbA1c (%) (6,01 ± 0,45 vs. 5,66 ± 0,41; p < 0,05) and increase of vWF:Ag (%) (148,08 ± 65,10 vs. 306,77 ± ± 146,63; p < 0,01) were observed.

Conclusions Our study suggests the advantage of trandolapril monotherapy on carbohydrate metabolism seen in polymetabolic syndrome but not on endothelial function despite satisfactory blood pressure control. We observed significant increase of vWF:Ag level which may be a local effect of ACE inhibitor on already injured endothelium.

Get Citation

Keywords

essential arterial hypertension; von Willebrand Factor; polymetabolic syndrome

About this article
Title

The Impact of Trandolapryl on Some Metabolic Disturbances and Endothelium Dysfunction in Non-treated Essential Hypertensive Patients

Journal

Arterial Hypertension

Issue

Vol 5, No 2 (2001)

Pages

115-124

Published online

2001-06-15

Bibliographic record

Nadciśnienie tętnicze 2001;5(2):115-124.

Keywords

essential arterial hypertension
von Willebrand Factor
polymetabolic syndrome

Authors

Marek Kretowicz
Małgorzata Ukleja-Adamowicz
Paweł Stróżecki
Krzysztof Buczkowski
Katarzyna Klucz
Ryszard Paczuski
Grażyna Odrowąż-Sypniewska
Jacek Manitius

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl